Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 17/20 | 0.54 |
| ▸ | KDR | P35968 | 17/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6888387 | 0.88 | CDK1 (0.47) | CDK1KDR | |
| SCHEMBL6511553 | 0.88 | EGFR (0.41) | CDK1KDRJAK2FLT3JAK1 | |
| SCHEMBL6519463 | 0.87 | CDK1 (0.58) | CDK1KDRJAK2JAK1JAK3 | |
| SCHEMBL6509043 | 0.86 | CDK1 (0.61) | CDK1KDRJAK2FLT3ABL1 | |
| SCHEMBL6517883 | 0.82 | CDK1 (0.65) | CDK1KDRABL1PDGFRBSRC | |
| SCHEMBL6510348 | 0.77 | EGFR (0.40) | CDK1KDR | |
| SCHEMBL6888385 | 0.77 | CDK1 (0.53) | CDK1KDR | |
| SCHEMBL6512138 | 0.76 | CDK1 (0.37) | CDK1KDR | |
| SCHEMBL6034496 | 0.75 | KDR (0.62) | CDK1KDR | |
| SCHEMBL6511549 | 0.71 | CDK1 (0.49) | CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FLT4, FGFR1 | CDK1 435/4885KDR 8/4885JAK2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.